Skip to content
DraconiticResearch
Search Sources API
197,788 studies31 sourcesUpdated 27 min ago
Peer-reviewedCC BY 4.0Amino Acids

Beta-alanine provides partial protection against the development of symptoms driven by glucocorticoid excess

  • Samuel R. Heaselgrave1,2
  • Minghao Deng2
  • Gareth G. Lavery2
  • Craig L. Doig2
  1. 1Center of Hypothalamic Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., MC: 9077, Y06322A, Dallas, TX 75390-9077 USA
  2. 2Centre for Systems Health and Integrated Metabolic Research, Department of Biosciences, Nottingham Trent University, Nottingham, UK
Read full textDOICite

Abstract

Exogenous glucocorticoids are extensively used to combat a plethora of medical conditions. However, a sustained excess of exogenous glucocorticoids causes several adverse metabolic conditions, most notably Cushing’s Syndrome which presents with a well-defined phenotype. Herein we determine the ability of the non-proteogenic amino acid, beta alanine (BA) to mitigate the development of Cushing’s Syndrome. Female C57BL/6J mice were treated with high dose corticosterone or a vehicle control with or without BA for 3 weeks. Indirect calorimetry was conducted during the final week of treatment and glucose tolerance was assessed upon completion. BA partially attenuated the development of the Cushingoid phenotype with a reduction in central adipose accumulation, bodyweight gain and trended reduction in liver weight. Despite this reduction, BA also reversed the apparent corticosterone induced increase in energy expenditure (EE), whilst further restricting mice to carbohydrate utilisation. However, BA completely preserved glucose tolerance. We identify a novel therapeutic role of BA in mitigating the development of some of the symptoms associated with exogenous glucocorticoid treatment, most notably glucose intolerance. Further investigation is now required to determine the extent of BA’s protection as well as the mechanisms involved.

Related

  1. Integration of liver methylome and transcriptome provides new insights into the regulation of ovarian development genes in spotted scat (Scatophagus argus)
    Mei-Zhen Zhang, Yu Li, Kai-Zhi Jiao +7
    BMC GenomicsPeer-reviewedCC BY-NC-ND 4.0PhysiologyCrossref
  2. Development and Preliminary Psychometric Evaluation of a Questionnaire on Comprehensive Protection, Quality, and Humanization in Pediatric Hospital Care
    Germán Rojas Loyola, Begoña Polonio-López, Juan José Criado-Alvarez +1
    Pediatric reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Development and psychometric validation of the sun exposure and protection questionnaire (SEPQ) in young adults: a university-based validation study
    Sari Taha, Mohammad Darwaze, Nour Ghareeb +4
    Scientific ReportsPeer-reviewedCC BY 4.0Full textGeneral medicineCrossref
  4. Beyond Negative Bias: Disrupted Positive Valence Processing and Asynchronous Hot–Cool Development in Youth Internalizing Symptoms
    Jiangli Wu, Xiaoxia Hu, Ruoyu Qiu +6
    PsyArXivPreprintCC BY 4.0Full textNeurosciencePsychiatry & mental healthOSF
  5. Development of a Knowledge Map for Managing Symptoms of Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation
    Li Shanshan, Cai Huili, Chen Mingxia +2
    Computers, Informatics, NursingPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC

Cite

BibTeXRIS
BibTeX
@article{heaselgrave2026betaalanine,
  title = {{Beta-alanine provides partial protection against the development of symptoms driven by glucocorticoid excess}},
  author = {Samuel R. Heaselgrave and Minghao Deng and Gareth G. Lavery and Craig L. Doig},
  journal = {Amino Acids},
  year = {2026},
  month = jul,
  doi = {10.1007/s00726-026-03536-y},
  url = {https://doi.org/10.1007/s00726-026-03536-y},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Beta-alanine provides partial protection against the development of symptoms driven by glucocorticoid excess
AU  - Samuel R. Heaselgrave
AU  - Minghao Deng
AU  - Gareth G. Lavery
AU  - Craig L. Doig
PY  - 2026
DA  - 2026/07/23
JO  - Amino Acids
DO  - 10.1007/s00726-026-03536-y
UR  - https://doi.org/10.1007/s00726-026-03536-y
AB  - Exogenous glucocorticoids are extensively used to combat a plethora of medical conditions. However, a sustained excess of exogenous glucocorticoids causes several adverse metabolic conditions, most notably Cushing’s Syndrome which presents with a well-defined phenotype. Herein we determine the ability of the non-proteogenic amino acid, beta alanine (BA) to mitigate the development of Cushing’s Syndrome. Female C57BL/6J mice were treated with high dose corticosterone or a vehicle control with or without BA for 3 weeks. Indirect calorimetry was conducted during the final week of treatment and glucose tolerance was assessed upon completion. BA partially attenuated the development of the Cushingoid phenotype with a reduction in central adipose accumulation, bodyweight gain and trended reduction in liver weight. Despite this reduction, BA also reversed the apparent corticosterone induced increase in energy expenditure (EE), whilst further restricting mice to carbohydrate utilisation. However, BA completely preserved glucose tolerance. We identify a novel therapeutic role of BA in mitigating the development of some of the symptoms associated with exogenous glucocorticoid treatment, most notably glucose intolerance. Further investigation is now required to determine the extent of BA’s protection as well as the mechanisms involved.
SN  - 0939-4451
SN  - 1438-2199
ER  -